Apr 11 2024
Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist

Posted at Apr 11 2024
h in News by Cara Weaver

PLYMOUTH MEETING, Pa., April 11, 2024 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists with the potential for a best-in-class clinical profile.

Check out the full article here or the PDF version here.

Print page

Apr 11 2024 Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist

2 events, 25

2 events, 25

1 event, 26

1 event, 26

2 events, 27

2 events, 27

1 event, 28

1 event, 28

1 event, 29

1 event, 29

1 event, 30

1 event, 30

0 events, 1

0 events, 1

2 events, 2

2 events, 2

2 events, 3

2 events, 3

GivingTuesday 2024

GivingTuesday 2024

2 events, 4

2 events, 4

2 events, 5

2 events, 5

1 event, 6

1 event, 6

1 event, 7

1 event, 7

0 events, 8

0 events, 8

2 events, 9

2 events, 9

1 event, 10

1 event, 10

2 events, 11

2 events, 11

2 events, 12

2 events, 12

1 event, 13

1 event, 13

1 event, 14

1 event, 14

0 events, 15

0 events, 15

2 events, 16

2 events, 16

1 event, 17

1 event, 17

2 events, 18

2 events, 18

1 event, 19

1 event, 19

1 event, 20

1 event, 20

1 event, 21

1 event, 21

0 events, 22

0 events, 22

2 events, 23

2 events, 23

Apr 11 2024
Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist